Objectives To develop an easily applicable diagnostic scoring method to determine the presence of peptic ulcers in dyspeptic patients in a primary care setting; to evaluate whether Helicobacter pylori testing adds value to history taking. Design Cross sectional study. Setting General practitioners' offices in the Utrecht area of the Netherlands. Participants 565 patients consulting a general practitioner about dyspeptic symptoms of at least two weeks' duration.
Introduction
Dyspepsia is a common problem. 1 The vast majority of patients presenting with dyspepsia in primary care have no organic disease, but a few patients have peptic ulceration and would benefit from specific treatmentnotably, those whose ulcer is related to Helicobacter pylori infection.
2 Although the number of peptic ulcers unrelated to H pylori is increasing, most ulcers are related to H pylori infection, which accounts for significant morbidity and mortality. 3 4 Non-invasive "test and treat" policies for H pylori infection have been promoted in order to improve early detection and treatment of ulcers in dyspeptic patients. [5] [6] [7] [8] [9] [10] In a recently published systematic review, Moayyedi et al stated that eradication of H pylori is also of modest benefit in patients with non-ulcer dyspepsia. 11 This benefit, however, seems too small to make promotion of test and treat strategies for H pylori for all dyspeptic patients advisable (15 patients with non-ulcer dyspepsia need to receive H pylori eradication therapy to reduce dyspepsia in one patient). Furthermore, although a test and treat strategy or the alternative strategy of direct endoscopy in all dyspeptic patients may be cost effective, this cost effectiveness would be reduced in the primary care setting, with its lower prevalence of peptic ulcers. 12 In addition, a strategy involving routine endoscopy would be a considerable burden to patients.
Many dyspepsia guidelines, including those of the Dutch College of General Practitioners, still recommend restricting H pylori eradication to patients with a proved peptic ulcer. 13 Thus preselection by general practitioners, based on symptoms and signs, of dyspeptic patients at increased risk of having peptic ulcer disease remains crucial. So far, such symptom based diagnostic algorithms for predicting the presence of peptic ulcer have performed rather poorly, although the statistical power of most studies was limited. [14] [15] [16] [17] [18] [19] [20] [21] [22] Furthermore, the value of a diagnostic method combining optimal history taking with additional H pylori testing has not been explored.
We carried out a diagnostic study to determine which components of history taking independently contribute to predicting the presence of peptic ulcer disease in patients with dyspepsia presenting to general practice and whether H pylori testing provides any added diagnostic value. In addition, we aimed to develop an easily applicable scoring system to aid the diagnosis of peptic ulcer in primary care.
Methods
Data were obtained from three different studies performed at the University Medical Center, Utrecht, with similar inclusion and exclusion criteria, in primary care patients with dyspeptic symptoms who were referred to open access endoscopy facilities in the greater Utrecht area between June 1996 and January 2000. Participants were eligible for this diagnostic study if they had had dyspeptic symptoms for at least two weeks before visiting their general practitioner. Patients were excluded if they were pregnant; presented with weight loss, anaemia, dysphagia, gastric bleeding, or vomiting; or had previous gastric surgery.
Diagnostic procedures
Age, sex, medical history, smoking behaviour, comorbidity, medication, and current symptoms were recorded by the general practitioner on a standard form. The H pylori status of all patients was subsequently determined with at least one of the following tests: a whole blood test (BM-Test Helicobacter pylori; Roche Diagnostics, Rotkreuz, Switzerland), an enzyme linked immunosorbant assay (ELISA) (Pyloriset EIA-G; Orion Diagnostics, Espoo, Finland), and a carbon-13 urea breath test (Pylobactell; BSIA/Torbett Laboratories, Chatham, UK). If one of these tests had positive results, the patient was considered to be infected with H pylori. Finally, all patients were referred for endoscopy in one of the participating centres to establish a diagnosis. The study was approved by the medical ethics committee of the University Medical Center, Utrecht, and written informed consent was obtained from all participants.
Outcome definition
The outcome of the study was the presence or absence of peptic ulcer disease. A peptic ulcer was considered to be present when a duodenal or gastric ulcer, erosive gastritis, or duodenitis was detected endoscopically.
Data analysis
The (univariate) association between each potential diagnostic determinant obtained from history taking and the presence of peptic ulcer disease was quantified by using odds ratios and 95% confidence intervals. All determinants with P < 0.25 were then entered together in a multivariate logistic regression model to evaluate which were independently associated with the presence of peptic ulcer disease. The model was reduced by excluding variables with P > 0.05 in order to retain a simpler diagnostic model containing only the strongest determinants of the presence of peptic ulcer disease.
This reduced model was extended with the H pylori test result to quantify the added value of the test result in predicting the presence or absence of peptic ulcer disease. The reliability (goodness of fit) of each of the diagnostic models was assessed by using the Hosmer and Lemeshow test, 23 and the ability to discriminate between patients with and without peptic ulcer was quantified by using the area under the receiver operating characteristic curve (ROC area). 24 The ROC area is a suitable measure to summarise the discriminative power of a diagnostic model and can range from 0.5 (no discrimination, like flipping a coin) to 1.0 (perfect discrimination). A value of 0.7-0.8 is considered to represent reasonable discrimination, and a value of > 0.8 is good discrimination. 25 Differences in diagnostic discriminative value between different (reduced and extended) models were estimated by comparing ROC areas, taking into account the correlation between the models as they were based on the same cases. 26 
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Subgroup analyses
We analysed the ability of subsets of relevant diagnostic determinants obtained from history taking to detect peptic ulcer disease. Taking into account the independent diagnostic determinants, we identified groups of patients at high and low risk by using the odds ratios of the history model. The added value of a non-invasive H pylori test in detecting peptic ulcer disease in these subgroups was assessed by creating two by two tables and computing the 2 statistic and the posterior probability of a peptic ulcer following positive and negative H pylori tests.
Results
Complete data on medical history, current symptoms, and the diagnosis according to endoscopy were available for 565 of the 612 patients enrolled in the study (tables 1 and 2). Of these 565 patients, 38 (6.7%) had a peptic ulcer detected at endoscopy. The peptic ulcers were related to H pylori according to the non-invasive H pylori test in 22 (58%) of these 38 patients.
Age, history of peptic ulcer disease, smoking, pain on empty stomach, and the non-invasive H pylori test were associated with the presence or absence peptic ulcer disease and were selected for multivariate analyses (table 3) . Of the four history variables, smoking, pain on an empty stomach, and history of peptic ulcer disease were independent predictors of peptic ulcer disease. The ROC area of the history model based on these three items was 0.71 (95% confidence interval 0.62 to 0.81). Adding the non-invasive H pylori test to the model increased the ROC area to 0.75 (0.66 to 0.83) (figure). This increase was not significant (P = 0.46). Both models had sufficient goodness of fit.
Although the H pylori test result was independently associated with the presence or absence of peptic ulcer disease in the total patient group, as indicated by the odds ratios with 95% confidence interval in table 3, it did not contribute to a better discrimination beyond history taking, as indicated by the small increase in ROC area. We went on to estimate the value of H pylori testing in subgroups of patients at high or low risk of peptic ulcer disease, based on history taking. Using the odds ratios in table 3, a scoring method was developed, including history of peptic ulcer disease (weight = 2) and smoking and pain on empty stomach (both weight = 1). High risk was defined as a score of >2 and low risk as < 2; 135 patients at high risk and 430 patients at low risk were identified. The prior probability (prevalence) of peptic ulcer disease was 16% (22/135) in the high risk group and 4% (16/430) in the low risk group (table 4). In the high risk group, a positive H pylori test result increased the probability (positive predictive value) from 16% to 26% (14/54). A negative test result decreased the probability (negative predictive value) from 16% to 10% (8/81). In the low risk group, the positive predictive value was 7% and the negative predictive value was 2.5%.
Discussion
Our study indicates that H pylori testing in all patients with dyspepsia in primary care has no value in addition to history taking for the diagnosis of peptic ulcer disease. However, in a subgroup of patients at high risk of peptic ulcer disease (based on scoring including the three history variables of smoking, pain on empty stomach, and history of peptic ulcer), a non-invasive H pylori test provides additional diagnostic information as indicated by relevant post-test changes in the probability of the presence or absence of peptic ulcer disease.
Applying a test and treat strategy (performing a non-invasive H pylori test, initiating eradication therapy in patients with a positive result, and providing acid suppressive therapy to the remaining patients) in all patients presenting with dyspepsia in primary care would lead to prescription of eradication therapy in up to 31% of all patients, whereas a peptic ulcer is present in only 12.6% of these. This would lead to unnecessary costs and potential side effects, including the development of resistance to antibiotics. Restriction of non-invasive H pylori testing to patients preselected as being at high risk according to our scoring rule based on history variables seems a more appropriate recommendation. The risk of these patients having a peptic ulcer is considerable (16.3%), and peptic ulcer treatment could be initiated without prior endoscopy. An H pylori test and treat strategy in high risk patients would result in prescription of eradication therapy in only 9.6% of all dyspeptic patients, 26% of whom would have a peptic ulcer. In this high risk group, the ratio of patients "correctly" (those with peptic ulcer) or "incorrectly" (those without peptic ulcer) receiving eradication therapy is 1:3, whereas the corresponding ratio in the total group of dyspeptic patients presenting in primary care is 1:7.
Moayyedi et al reported in a recent systematic review that an early H pylori test and treat strategy might be cost effective in non-ulcer dyspepsia, and Lassen et al concluded from their own research that a test and treat strategy is as efficient and safe as prompt endoscopy for the management of dyspeptic patients in primary care. 11 12 We believe that both groups failed to recognise the benefit of preselection of patients by adequate history taking before H pylori testing is considered and that implementation of their recommendations would result in many unjustified prescriptions for eradication of H pylori.
Limitations
Several limitations of our study need to be addressed. Our analyses were based on data from three previous studies by our group. As a result, different H pylori tests with varying characteristics were used. This might have accounted for an underestimation of H pylori infections and peptic ulcers related to H pylori. 28 29 This is confirmed by the fact that the rate of H pylori infection found at endoscopy in our patients (by culture, histology, or rapid urease testing of biopsy specimens) was higher (41%) than the rate found with non-invasive tests (31%). Use of more reliable non-invasive test methods would have led to more peptic ulcers related to H pylori being detected, which would have improved the performance of our scoring method. The scoring method awaits prospective evaluation in other primary care populations; the performance of the scoring method critically depends on the prevalence of H pylori infection and peptic ulcer disease. Currently, the rule is being tested by several groups of general practitioners in the Netherlands.
Conclusions
We conclude that adding testing for H pylori infection to history taking might be useful only in patients at high risk of having peptic ulcer disease. It would avoid endoscopies in some patients and lead to more accurate treatment of peptic ulcer disease in most patients.
We thank Roche Diagnostics (Almere, Netherlands) and the Imphos/Zambon group (Amersfoort, Netherlands) for supplying the whole blood tests and ELISAs and Peter Zuithoff for statistical advice.
Contributors: MEN, NJW, AWH, and AJPMS proposed the idea for the study. CFW performed the literature search. The study was designed by MEN, AWH, TJMV, and NJW. CFW collected the data. The data and results were interpreted by CFW, KGM, MEN, and AHW. CFW, KGM, MEN, and AWH wrote the initial draft of the paper; NJW, AJPMS, and TJMV contributed to the final version. AWH and MEN are guarantors for this paper.
Funding: research grant from the Dutch Health Care Insurance Council.
Competing interests: CFW has received reimbursement for attending symposia from AstraZeneca, Abbott, and JanssenCilag. NJW and MEN have received reimbursements for attending symposia, fees for organising postgraduate education, and funds for research from AstraZeneca, Janssen-Cilag, BykGulden, Abbott, and GlaxoWellcome. AJPMS has received funding for research and organising postgraduate education from AstraZeneca, BykGulden, Janssen-Cilag, GlaxoWellcome, Ferring, Aventis, Novartis, and Solvay. TJMV has received reimbursement for attending symposia from Abbott.
What is already known on this topic
In primary care, predicting the presence of peptic ulcer disease in dyspeptic patients on the basis of history taking is difficult Infection with Helicobacter pylori is associated with peptic ulcer disease Many non-invasive H pylori tests are available, but the value they add to history taking is not known
What this paper adds
Three simple questions from history taking can distinguish between patients at high and low risk of peptic ulcer disease
In uninvestigated patients with dyspepsia in primary care, H pylori testing adds nothing to optimal history taking in the diagnosis of peptic ulcer disease
In patients at high risk of peptic ulcer disease it is useful to test for and treat H pylori infection A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials 
Abstract
Objective To create a risk score for death from cardiovascular disease that can be easily used. Design Data from eight randomised controlled trials of antihypertensive treatment. Setting Europe and North America. Participants 47 088 men and women from trials that had differing age ranges and differing eligibility criteria for blood pressure. Main outcome measure 1639 deaths from cardiovascular causes during a mean 5.2 years of follow up. Results Baseline factors were related to risk of death from cardiovascular disease using a multivariate Cox model, adjusting for trial and treatment group (active versus control). A risk score was developed from 11 factors: age, sex, systolic blood pressure, serum total cholesterol concentration, height, serum creatinine concentration, cigarette smoking, diabetes, left ventricular hypertrophy, history of stroke, and history of myocardial infarction. The risk score is an integer, with points added for each factor according to its association with risk. Smoking contributed more in women and in younger age groups. In women total cholesterol concentration mattered less than in men, whereas diabetes had more of an effect. Antihypertensive treatment reduced the score. The five year risk of death from cardiovascular disease for scores of 10, 20, 30, 40, 50, and 60 was 0.1%, 0.3%, 0.8%, 2.3%, 6.1%, and 15.6%, respectively. Age and sex distributions of the score from the two UK trials enabled individual risk assessment to be age and sex specific. Risk prediction models are also presented for fatal coronary heart disease, fatal stroke, and all cause mortality. Conclusion The risk score is an objective aid to assessing an individual's risk of cardiovascular disease, including stroke and coronary heart disease. It is useful for physicians when determining an individual's need for antihypertensive treatment and other management strategies for cardiovascular risk.
Introduction
The management of patients with hypertension often focuses on drugs and other means of controlling blood pressure without adequate regard to their overall risk of morbidity and mortality from cardiovascular disease. The goal of treatment is to reduce the risk of stroke and heart disease and to prevent premature death. Hence a range of personal factors should be considered in assessing a patient's overall cardiovascular risk. A recent inquiry emphasised the benefits of using charts or scores for cardiovascular risk in getting treatment decisions made alongside realistic estimates of patient susceptibility to cardiovascular disease. 1 Other scoring methods already exist for assessing risk, 2-9 but ours has several particularly useful features: it focuses on patients with raised blood pressure, and it assesses an individual's overall risk for all cardiovascular diseases, including stroke, rather than just coronary heart disease. Although the guidelines from the World Health Organization and International Society of Hypertension usefully classify hypertensive patients from low risk to very high risk of cardiovascular disease, 10 we present a more quantitative and discriminating risk score based on the mortality among participants in eight randomised controlled trials of antihypertensive treatment. We aimed to enable the calculation of risk of cardiovascular death within five years from a few personal factors.
Participants and methods
The individual data analysis of antihypertensive intervention trials (INDANA) database includes all the major randomised trials of antihypertensive drugs versus placebo or no intervention for which individual patient data were available in 1995. 11 
